Risuteganib (CAS No. 1307293-62-4) | GMP Supplier & Manufacturer

描述

Product Description

Risuteganib is a synthetic peptide belonging to the RGD (arginyl–glycyl–aspartic acid) class, a family of bioactive sequences known for their role in cell adhesion, integrin binding, and extracellular matrix signaling. Designed as an anti-integrin therapeutic peptide, Risuteganib is unique because it interacts with three integrin receptors simultaneously, downregulates oxidative stress, and restores homeostatic balance in retinal tissues.

The compound has gained prominence in recent years because of its relevance to ophthalmic research, particularly in dry age-related macular degeneration (dry AMD) — a leading cause of vision loss worldwide with limited therapeutic options. Unlike conventional therapies that primarily slow progression, Risuteganib’s mechanism seeks to re-establish cellular equilibrium within retinal pigment epithelial (RPE) cells, providing a restorative and protective model for researchers studying degenerative eye disease.

Importance in Retinal Research

The retina is constantly exposed to oxidative stress, which contributes to cell damage and progressive loss of vision in AMD. Integrins, which are transmembrane receptors involved in cell adhesion and signaling, play a central role in mediating inflammatory cascades and stress responses. By modulating integrin activity, Risuteganib:

• Reduces oxidative stress burden in RPE cells

• Restores cytoskeletal integrity and homeostatic equilibrium

• Enhances cell survival and metabolic resilience

• Provides a novel tool for translational AMD research

Beyond AMD, the ability of Risuteganib to regulate integrin activity has implications in broader neurodegenerative disease models, ocular disorders, and oxidative stress biology.

Comparative Advantages

• Multi-Integrin Targeting: Unlike single-target inhibitors, Risuteganib binds multiple integrins, amplifying its regulatory potential.

• Oxidative Stress Modulation: Provides dual benefits — not only suppressing damage but also restoring balance.

• Synthetic RGD-Class Design: Stable, reproducible, and optimized for peptide research applications.

• Translational Potential: Its unique mechanism supports advanced research into disease-modifying strategies rather than palliative interventions.

Product Specifications

Notes on Specifications

• Analytical Validation: Each batch undergoes HPLC, mass spectrometry, and peptide sequencing analysis.

• Formulation: Supplied lyophilized for maximum stability.

• End Use: Research-grade only, intended for laboratory investigations in retinal and integrin biology.

Mechanism of Action & Research Applications

Mechanism of Action

Risuteganib functions as a multi-integrin modulator. By interacting with integrin subtypes αvβ3, αvβ5, and α5β1, it directly influences cellular adhesion and signaling networks. The downstream consequences include:

• Reduced oxidative stress signaling

• Restoration of cytoskeletal architecture

• Modulation of extracellular matrix communication

• Enhancement of retinal pigment epithelium (RPE) cell survival

This is particularly important because integrins are key regulators of apoptosis, inflammatory signaling, and oxidative damage — all processes implicated in AMD progression.

Research Applications

1. Age-Related Macular Degeneration (AMD) – Tool compound for understanding integrin-mediated degeneration and homeostatic repair in dry AMD.

2. Oxidative Stress Biology – Studying how modulation of integrin receptors influences ROS levels and antioxidant defenses.

3. Retinal Pigment Epithelium Research – Investigating cytoskeletal remodeling and adhesion dynamics in RPE cells.

4. Neurodegeneration Studies – Potential applications in broader models of oxidative neurodegeneration beyond the eye.

5. Drug Development Benchmarking – Serves as a reference compound for integrin-based therapeutic development.

6. Cellular Homeostasis Studies – Provides insight into integrin-dependent survival mechanisms under stress.

Translational Insights

Because Risuteganib restores homeostatic balance instead of simply suppressing pathological activity, it represents a new paradigm in disease-modifying peptide research. It holds promise as a tool compound for regenerative approaches, especially in conditions where oxidative imbalance is central.

Side Effects (For Research Context Only)

In laboratory research models, potential observations associated with Risuteganib include:

• Transient alterations in integrin signaling that may affect normal cell adhesion.

• Oxidative rebound if improperly dosed in experimental setups.

• Species-specific differences in integrin distribution and responsiveness.

• Injection-related responses such as mild ocular inflammation in animal studies.

• Receptor compensation over prolonged exposure, potentially diminishing efficacy.

These considerations highlight the importance of carefully controlled dosing regimens and comparative studies across models.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• Risuteganib

• Risuteganib CAS 1307293-62-4

• Risuteganib peptide supplier

• Anti-integrin peptide research

• RGD-class peptide for AMD research

• Risuteganib oxidative stress studies

• Dry AMD integrin modulator peptide

• Retinal homeostasis peptide

• GMP-grade ophthalmology research peptide

• Risuteganib age-related macular degeneration research